Your browser doesn't support javascript.
Eosinophilic Esophagitis Patients Are Not at Increased Risk of Severe COVID-19: A Report From a Global Registry.
Zevit, Noam; Chehade, Mirna; Leung, John; Marderfeld, Luba; Dellon, Evan S.
  • Zevit N; Institute of Gastroenterology, Hepatology and Nutrition, Schneider Children's Medical Center of Israel, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: nzevit@gmail.com.
  • Chehade M; Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Leung J; Boston Specialists LLC, Boston, Mass; Department of Gastroenterology, Tufts Medical Center, Boston, Mass.
  • Marderfeld L; Division of Gastroenterology, The Ottawa Hospital IBD Centre, Ottawa, Ontario, Canada.
  • Dellon ES; Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC; Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine,
J Allergy Clin Immunol Pract ; 10(1): 143-149.e9, 2022 01.
Article in English | MEDLINE | ID: covidwho-1474685
ABSTRACT

BACKGROUND:

The impact of coronavirus disease 2019 (COVID-19) on eosinophilic esophagitis (EoE) and eosinophilic gastrointestinal diseases (EGIDs) is unknown.

OBJECTIVE:

We aimed to characterize patients with EoE and EGIDs who had COVID-19, assess severity of COVID-19 in the EoE/EGID population, and evaluate for COVID-19-induced EoE/EGID flares.

METHODS:

We established an online global registry collecting physician entered, deidentified data related to patient demographics, EoE/EGID disease features, comorbidities, and treatments, COVID-19 source of exposure, symptoms, illness severity, hospitalizations, and deaths.

RESULTS:

Ninety-four cases were reported between March 2020 and April 2021 (median age, 21 years; range, 1.5-53 years; 73% male). Most had atopy (73%), and 80% had isolated EoE. Before COVID-19, the EoE/EGID activity was reported as clinical remission in 51 (54%) and moderate in 20 (21%). EoE/EGID treatments at the time of COVID-19 included proton pump inhibitors 49 (52%), swallowed/topical steroids 48 (51%), and dietary elimination 34 (36%). COVID-19 symptoms included cough (56%), fever (49%), anosmia (21%), and ageusia (22%). Most patients with COVID-19 had a mild course (70%), with 15% asymptomatic, 12% moderate, and 2% severe. Three patients were hospitalized, and no intensive care unit admissions or deaths were reported. Mean time from first symptoms to resolution in symptomatic patients was 10 days (range, 1-90 days). A single EGID flare was reported during COVID-19.

CONCLUSIONS:

In a global EoE/EGID registry, relatively few COVID-19 cases have been reported. COVID-19 severity was comparable to the general population. Based on this registry, it does not appear that patients with EoE are at increased risk for severe COVID-19 infection or that COVID-19 leads to EGID flares.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Enteritis / Eosinophilic Esophagitis / COVID-19 Type of study: Experimental Studies / Prognostic study Limits: Adult / Female / Humans / Male / Young adult Language: English Journal: J Allergy Clin Immunol Pract Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Enteritis / Eosinophilic Esophagitis / COVID-19 Type of study: Experimental Studies / Prognostic study Limits: Adult / Female / Humans / Male / Young adult Language: English Journal: J Allergy Clin Immunol Pract Year: 2022 Document Type: Article